Many studies [49, 50] have reported that Bcl-2 is the prototypical inhibitor of apoptosis (type I programmed cell death) and is upregulated in 75% of pancreatic cancers, and that the high levels of Bcl-2 in pancreatic cancer confer a potent antiapoptotic signal as well as confer chemoresistance, and that Bcl-2 also regulates autophagy in pancreatic cancer [51]. Here, BCL2 is linked to familial pancreatic carcinoma.